# Decreased circulating dipeptidyl peptidase-4 activity after short-term intensive insulin therapy predicts clinical outcomes in patients with newly diagnosed type 2 diabetes

**Authors:** Jie Chen, Peiji Dai, Weijian Ke, Xuesi Wan, Juan Liu, Lijuan Xu, Haipeng Xiao, Yanbing Li, Liehua Liu

PMC · DOI: 10.3389/fendo.2024.1352002 · Frontiers in Endocrinology · 2024-02-27

## TL;DR

This study shows that a drop in a blood enzyme called DPP-4 after short insulin treatment may predict long-term diabetes remission in new patients.

## Contribution

The study identifies a novel predictive role of DPP-4 activity changes after insulin therapy for diabetes remission.

## Key findings

- DPP-4 activity decreased significantly after short-term insulin therapy in T2D patients.
- Greater DPP-4 reduction was associated with higher likelihood of 1-year diabetes remission.
- A non-linear threshold effect was observed between DPP-4 change and remission probability.

## Abstract

This study aims to investigate the changes in circulating dipeptidyl peptidase-4 (DPP-4) activity following short-term intensive insulin therapy (SIIT) in newly diagnosed type 2 diabetes (T2D) patients and to assess its potential in predicting long-term remission.

Ninety-five patients underwent SIIT for 2-3 weeks to attain and sustain near-normal glycemia. Insulin was then discontinued, and patients were followed for a year to evaluate glycemic outcomes. Biochemical tests, serum DPP-4 activity, and mixed meal tolerance tests were conducted at baseline, post-SIIT, and the 3-month follow-up.

DPP-4 activity decreased from 44.08 ± 9.58 to 40.53 ± 8.83 nmol/min/mL after SIIT (P<0.001). After three months post-SIIT, DPP-4 activity remained stable in the remission group (39.63 ± 8.53 nmol/L) but increased in the non-remission group (42.34 ± 6.64 nmol/L). This resulted in a more pronounced decrease in DPP-4 activity from baseline in the remission group (-3.39 ± 8.90 vs. -1.10 ± 8.95, P = 0.035). Logistic regression analyses showed that patients with greater DPP-4 activity reduction had a higher likelihood of 1-year remission (70% vs. 51.1%, OR: 7.939 [1.829, 34.467], P = 0.006 in the fully adjusted model). A non-linear relationship between △DPP-4 and 1-year remission rate was observed, with a clear threshold and saturation effect.

Circulating DPP-4 activity significantly decreases after SIIT. The change in circulating DPP-4 activity during the 3-month post-treatment phase has the potential to predict long-term remission.

## Linked entities

- **Proteins:** DPP4 (dipeptidyl peptidase 4)
- **Diseases:** type 2 diabetes (MONDO:0005148), T2D (MONDO:0005148)

## Full-text entities

- **Genes:** DPP4 (dipeptidyl peptidase 4) [NCBI Gene 1803] {aka ADABP, ADCP2, CD26, DPPIV, TP103}
- **Diseases:** T2D (MESH:D003924)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC10929261/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC10929261/full.md

## References

37 references — full list in the complete paper: https://tomesphere.com/paper/PMC10929261/full.md

---
Source: https://tomesphere.com/paper/PMC10929261